Published in N Engl J Med on January 31, 2002
Oral and topical corticosteroids in bullous pemphigoid. N Engl J Med (2002) 0.75
A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med (2002) 5.58
Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol (2005) 3.04
Long-term use of nonsteroidal anti-inflammatory drugs decreases the risk of cutaneous melanoma: results of a United States case-control study. J Invest Dermatol (2011) 2.45
Suicidal ideation, mental health problems, and social impairment are increased in adolescents with acne: a population-based study. J Invest Dermatol (2010) 2.18
Topical calcineurin inhibitors labeling: putting the "box" in perspective. Arch Dermatol (2006) 2.16
Determinants of quality of life in patients with psoriasis: a study from the US population. J Am Acad Dermatol (2004) 1.94
How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review. J Invest Dermatol (2009) 1.87
Clinical severity of psoriasis in last 20 years of PUVA study. Arch Dermatol (2007) 1.83
The prevalence of psoriasis in African Americans: results from a population-based study. J Am Acad Dermatol (2005) 1.68
Impact of psoriasis on health-related quality of life decreases over time: an 11-year prospective study. J Invest Dermatol (2006) 1.57
The increased risk of skin cancer is persistent after discontinuation of psoralen+ultraviolet A: a cohort study. J Invest Dermatol (2003) 1.53
Members of the national psoriasis foundation: more extensive disease and better informed about treatment options. Arch Dermatol (2005) 1.45
Severe cutaneous reactions to sulfadoxine-pyrimethamine and trimethoprim-sulfamethoxazole in Blantyre District, Malawi. Am J Trop Med Hyg (2006) 1.24
Traditional systemic treatments have not fully met the needs of psoriasis patients: results from a national survey. J Am Acad Dermatol (2005) 1.16
Telaprevir-related dermatitis. JAMA Dermatol (2013) 0.98
The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with nonsteroidal antiinflammatory drugs: a multinational perspective. J Rheumatol (2003) 0.97
Reported use of photosensitizing medications and basal cell and squamous cell carcinoma of the skin: results of a population-based case-control study. J Invest Dermatol (2007) 0.96
High levels of ultraviolet B exposure increase the risk of non-melanoma skin cancer in psoralen and ultraviolet A-treated patients. J Invest Dermatol (2005) 0.85
Investigation into the multidimensional genetic basis of drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics (2007) 0.82
Use of biological agents in patients with moderate to severe psoriasis: a cohort-based perspective. Arch Dermatol (2007) 0.81
Impact of bar-code labeling of clinical photographs on patient care and practice workflow. Arch Dermatol (2012) 0.81
The psychometric properties of the psoriasis disability index in United States patients. J Invest Dermatol (2005) 0.81
Oral retinoid use reduces cutaneous squamous cell carcinoma risk in patients with psoriasis treated with psoralen-UVA: a nested cohort study. J Am Acad Dermatol (2003) 0.80
A promising step forward in psoriasis therapy. JAMA (2003) 0.79
STROBE: a Beacon for observational studies. Arch Dermatol (2008) 0.78
The misperception that clinical trial data reflect long-term drug safety: lessons learned from Efalizumab's withdrawal. Arch Dermatol (2009) 0.78
Topical tretinoin, another failure in the pursuit of practical chemoprevention for non-melanoma skin cancer. J Invest Dermatol (2012) 0.78
Psoralen plus ultraviolet A does not increase the risk of cataracts: a 25-year prospective study. J Am Acad Dermatol (2007) 0.78
Going beyond associative studies of psoriasis and cardiovascular disease. J Invest Dermatol (2012) 0.77
Proportion of lifetime UV dose received by age 18, what Stern et al actually said in 1986. J Invest Dermatol (2005) 0.75
How epidemiology has contributed to a better understanding of skin disease. J Invest Dermatol (2011) 0.75
Assessing the safety of immunologic modifiers for the treatment of chronic disease: the psoriasis paradigm. J Invest Dermatol (2003) 0.75
Poor metrics and lost opportunity. J Am Acad Dermatol (2010) 0.75
Incidence and risk factors associated with a second squamous cell carcinoma or basal cell carcinoma in psoralen + ultraviolet a light-treated psoriasis patients. J Invest Dermatol (2002) 0.75
Questions & answers. Of all the treatments that promise to improve the appearance of aging skin, which ones have been medically proven to actually work? Health News (2004) 0.75
Insuring rapid and robust safety assessment. J Invest Dermatol (2004) 0.75
Isotretinoin prescribing: finding a balance between benefit and risk. Pharmacoepidemiol Drug Saf (2005) 0.75
Putting iatrogenic risk in perspective: basal cell cancer in PUVA patients and Australians. J Invest Dermatol (2009) 0.75
Factors Associated with Receiving Biologics or Classic Systemic Therapy for Moderate-to-Severe Psoriasis: Evidence from the PSONET Registries. Acta Derm Venereol (2016) 0.75
The reduced Impact of Psoriasis Questionnaire has good psychometric properties in Italian patients. Dermatology (2007) 0.75